Stockholders' Equity (Tables)
|
3 Months Ended |
Mar. 31, 2017 |
|---|
| Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
|
| Schedule of Share-based Compensation, Activity |
The following table summarizes the stock-based compensation expense from stock option awards, restricted common stock awards, employee stock purchase programs and warrants granted by Fortress for the three months ended March 31, 2017 and 2016: | | | For the Three Months Ended March 31, | | | ($ in thousands) | | 2017 | | 2016 | | | Employee awards | | $ | 1,830 | | $ | 1,584 | | | Non-employee awards | | | 13 | | | 3 | | | Fortress Companies (1) | | | 1,086 | | | 1,279 | | | Total stock-based compensation expense | | $ | 2,929 | | $ | 2,866 | | | | (1) | Consists of approximately $5,000 of Avenue's compensation expenses, approximately $1.0 million of Checkpoint's compensation expenses, approximately $46,000 of JMC's compensation expenses, approximately $47,000 of Helocyte's compensation expenses and approximately $8,000 of Cellvation's compensation expenses on equity grants for the three months ended March 31, 2017. |
|
| Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable |
The following table summarizes Fortress stock option activities excluding activity related to Fortress Companies:
| | | | | | | | | Weighted | | | | | | | | | | | average | | | | | | | Weighted | | Total weighted | | remaining | | | | | | | average | | average intrinsic | | contractual life | | | | | Number of shares | | exercise price | | value | | (years) | | | Options vested and expected to vest at December 31, 2016 | | | 1,130,501 | | $ | 3.73 | | $ | 602,451 | | | 4.93 | | | No activity | | | - | | | - | | | - | | | - | | | Options vested and expected to vest at March 31, 2017 | | | 1,130,501 | | $ | 3.73 | | $ | 1,216,285 | | | 4.69 | | | Options vested and exercisable | | | 1,105,501 | | $ | 3.71 | | $ | 1,216,285 | | | 4.66 |
|
|
| Nonvested Restricted Stock Shares Activity |
The following table summarizes Fortress’s restricted stock and restricted stock unit award activity, excluding activity related to Fortress Companies (which is discussed below): | | | | | Weighted average | | | | | Number of shares | | grant price | | | Unvested balance at December 31, 2016 | | | 10,094,095 | | $ | 2.49 | | | Restricted stock granted | | | 1,325,396 | | | 2.70 | | | Restricted stock vested | | | (213,333) | | | 2.75 | | | Restricted stock units granted | | | 215,000 | | | 3.61 | | | Restricted stock units vested | | | (41,250) | | | 3.54 | | | Unvested balance at March 31, 2017 | | | 11,379,908 | | $ | 2.53 | |
|
| Schedule of Warrant Activities |
The following table summarizes Fortress warrant activities, excluding activities related to Fortress Companies:
| | | | | | | | | Weighted average | | | | | | | | | Total weighted | | remaining | | | | | | | Weighted average | | average intrinsic | | contractual life | | | | | Number of shares | | exercise price | | value | | (years) | | | Outstanding as of December 31, 2016 | | | 2,263,453 | | $ | 3.62 | | $ | 79,800 | | | 4.74 | | | Granted | | | 167,946 | | | 3.37 | | | - | | | 4.96 | | | Outstanding as of March 31, 2017 | | | 2,431,399 | | $ | 3.60 | | $ | 209,800 | | | 2.37 | | | Exercisable as of March 31, 2017 | | | 471,399 | | $ | 6.08 | | $ | 139,800 | | | 1.98
| |
|
| Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions |
The fair value of options granted in 2017 was estimated using the following assumptions: | | | March 31, | | | | | 2017 | | | Risk-free interest rate | | | 1.93% - 2.22 | % | | Expected dividend yield | | | - | % | | Expected term in years | | | 5.38 - 6.98 | % | | Expected volatility | | | 103.98% - 105.95 | % |
|